


BU Sponsored Research Expenditure Data: Expenditures YTD Comparison

This data represents a summary comparison of Sponsored Research Expenditures, direct and F&A, for each BU School and College of current year against last year. Anomalies include School of Law which is directly attributed to the CARB-X award funded by 5 different Funders including, BARDA and Wellcome Trust. Excluding CARB-X, Sponsored Research has a year over year change of \$21,677,450 or 6%.

Please note that Financial Aid, while set up as a Sponsored Research Award, is excluded from this analysis.

	June FY18 YTD			June FY19 YTD			FY18 to FY19	
	Direct	F&A	Total	Direct (\$)	F&A (\$)	Total (\$)		
AIC	\$ 10,484,348	\$ 3,530,294	\$ 14,014,642	\$ 12,664,651	\$ 4,212,932	\$ 16,877,583	↑	20%
CAS	\$ 40,641,391	\$ 16,464,255	\$ 57,105,646	\$ 42,013,337	\$ 18,150,210	\$ 60,163,547	↑	5%
COM	\$ 148,013	\$ 22,391	\$ 170,405	\$ 58,266	\$ (367)	\$ 57,899	↓	-66%
ENG	\$ 29,290,627	\$ 12,966,790	\$ 42,257,417	\$ 29,707,467	\$ 13,594,600	\$ 43,302,067	↑	2%
CFA	\$ 29,643	\$ -	\$ 29,643	\$ 25,000	\$ -	\$ 25,000	↓	-16%
MET	\$ 653	\$ 0	\$ 653	\$ 38,504	\$ -	\$ 38,504	↑	5795%
NEIDL	\$ 11,800,812	\$ 3,385,007	\$ 15,185,819	\$ 12,832,761	\$ 3,823,220	\$ 16,655,981	↑	10%
PARDEE	\$ 240,301	\$ 22,482	\$ 262,783	\$ 822,635	\$ 22,937	\$ 845,572	↑	222%
QST	\$ 271,094	\$ 94,977	\$ 366,071	\$ 412,312	\$ 118,625	\$ 530,937	↑	45%
SAR	\$ 8,433,034	\$ 3,544,760	\$ 11,977,793	\$ 8,998,969	\$ 3,919,931	\$ 12,918,900	↑	8%
SDM	\$ 6,035,047	\$ 2,401,757	\$ 8,436,804	\$ 6,505,422	\$ 2,644,722	\$ 9,150,143	↑	8%
SED	\$ 5,910,923	\$ 1,112,403	\$ 7,023,326	\$ 6,123,092	\$ 1,101,597	\$ 7,224,690	↑	3%
LAW	\$ 21,871,011	\$ 1,490,584	\$ 23,361,594	\$ 49,490,402	\$ 1,856,455	\$ 51,346,857	↑	120%
MED	\$ 96,862,158	\$ 33,537,997	\$ 130,400,155	\$ 97,012,409	\$ 36,395,540	\$ 133,407,949	↑	2%
SPH	\$ 31,076,066	\$ 9,376,103	\$ 40,452,169	\$ 34,544,898	\$ 10,755,097	\$ 45,299,996	↑	12%
SSW	\$ 4,590,801	\$ 1,050,073	\$ 5,640,873	\$ 6,487,454	\$ 1,156,100	\$ 7,643,554	↑	36%
STH	\$ 360,826	\$ 26,546	\$ 387,372	\$ 432,773	\$ 25,881	\$ 458,655	↑	18%
Other	\$ 5,223,150	\$ 28,938	\$ 5,252,087	\$ 5,947,839	\$ 60,984	\$ 6,008,823	↑	14%
Total	\$ 273,269,897	\$ 89,055,358	\$ 362,325,254	\$ 314,118,190	\$ 97,838,465	\$ 411,956,655	↑	14%

Research Volume by Sponsor (000's)




This chart shows a year over year comparison of Research Volume by Sponsor. Please note that Financial Aid, while set up as a Sponsored Research Award, is excluded from this analysis.

The Federal Government is our largest sponsor. As Federal funding is harder to achieve, Faculty must look to other Sponsor types to support their research when we reach the point of flat and/or declining Federal Funding.

BU Sponsored Research Expenditure Data: F&A Revenue

F&A Revenue against Budget (000's)




This chart represents FY2019 F&A Revenue for the three Medical Campus Schools, NEIDL, CRC, and LAW excluding Financial Aid.

Given the reliance BU has on sponsored research F&A revenue, it is important to understand the relationship between actual revenue incurred and Budget as swings in a negative direction will be impactful to the bottom line.


In FY2019 YTD, Boston University F&A Actual Revenue is up 8.4% over Budget and up 13.2% over FY2018 YTD.

This chart shows a comparison of F&A effective rates over the last three fiscal years by School. Effective rates are calculated by dividing F&A by Direct Costs, including Fringe. For this comparison, we specifically removed the CARB-X award from CRC so as to not skew the results. Both CRC and MED are fairly consistent year over year. School of Dental Medicine has few awards at higher rates which leads to a higher effective rate. Over the last two years, School of Public Health has submitted proposals at full overhead. This change in practice has led to a higher effective rate for their school.

F&A Effective Rate



5 Year F&A Revenue YTD Trend



This chart depicts a comparison of F&A Revenue earned over the last five years.

FY2019 YTD shows significant growth in F&A due to fewer F&A waivers, the CARB-X Award, and consistently higher F&A Rates.